eyeforpharma Barcelona Conference, Expo & Awards 2019

eyeforpharma12 - 14 March 2019, Barcelona, Spain.
It's 2019, and it's time for something new. Attendance is ahead of expectations, eyeforpharma Barcelona is on track for over 1300 pharma decision makers from Sales, Marketing, Patient Engagement, Patient Advocacy, Medical Affairs, Digital, Market Access and RWE functions to fuse with health innovators, payers, patients, start-ups and cutting-edge tech.

On current projections, tickets will sell out this year. Ensure you have a place reserved at the only meeting where executives forge a new future for the pharma industry.

Medicine is just the beginning

Medicines are essential, yet they're rarely the entire solution. As we shift focus to outcomes, we need to be prepared to deliver value in whatever form is best for patients. The keynote sessions at eyeforpharma Barcelona will cover:
  • Value, driven.
    Change your mindset to reach beyond the incremental - and find bold solutions for real patients. Only then will outcomes be transformed.
  • Authenticity rules.
    Use greater patient insights to build trust with customers and fight for the best patient journey. Make education and credibility your mantra!
  • Tech is fundamental.
    See how digital ML & AI are delivering the data that rewrites your business plan, sets new standards and makes the connected future a reality.
  • Welcome new customers.
    Exceed elevated expectations by aligning to consumerisation - and setting new goals in wellbeing, prevention and regeneration.

New for 2019

The Innovation Stage

A showcase of bleeding-edge, industry-transforming science and new ideas which will open your eyes to the coming disruptions.

Real-World Evidence Europe Summit

For 2019 we've added our industry-leading Real-World Evidence Summit to the event to show the role RWE will play in the shift to value

The im-patient conference

Patient-focused conferences are usually designed by pharma. Until now! This time, patients have created the agenda and line-up.

Market Access Europe Summit

Market Access is vital for pharma's commercial success - that's why for 2019 it has been added as a key topic.

This is the world's biggest commercial pharma meeting and your opportunity to join 1300+ pharma leaders focused Sales, Marketing, Patient Engagement, Market Access, Medical Affairs and Real-World Evidence

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save €300 when you register here

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...